Constitutive activation of the phosphoinositide 3-kinase (PI3K)-AKT pathway is observed in up to 70% of acute myelogenous leukemia. To investigate the relevance of an intrinsic PI3K-AKT pathway activation in hematopoietic malignancies, we analysed the effect of point mutations in the catalytic (p110a) and regulatory (p85a) subunit of class IA PI3K. We demonstrated that mutations in the helical (E542K, E545A) and kinase domain (H1047R) of p110a constitutively activate the PI3K-AKT pathway and lead to factor-independent growth of early hematopoietic cells. Proliferation and survival of the cells were inhibited in a time-and dose-dependent manner using either PI3K or AKT inhibitors. The mammalian target of rapamycin (mTOR) was demonstrated to be important for mitogenic, but not antiapoptotic signaling of mutant p110a. In a syngenic mouse model, hematopoietic cells expressing mutated p110a induced a leukemia-like disease characterized by anemia, neoplastic infiltration of hematopoietic organs and 90% mortality within 5 weeks, whereas activated mutants of the receptor tyrosine kinase c-KIT led to 100% mortality within 10 days. Our data show that point mutations in the p110a subunit of class IA PI3K confer factor independence to hematopoietic cells in vitro and leukemogenic potential in vivo, but have lower transforming activity than a deregulated class III receptor tyrosine kinase.
Introduction
Acute myeloid leukemia (AML) is a complex disease characterized by the uncontrolled expansion of immature myeloid precursor cells. In contrast to AML cells, differentiation, proliferation and survival of normal hematopoietic cells is tightly regulated, in part by extracellular signals received from hematopoietic growth factor and cytokine receptors and the subsequent activation of multiple signal transduction pathways. Deregulated activation of signal transduction pathways in AML cells is known to play an important role in leukemogenesis.
The phosphoinositide 3-kinase (PI3K)-AKT pathway is an important signal transduction axis and regulates survival, growth and proliferation of hematopoietic cells through a variety of downstream targets. In mammalian cells, PI3-kinases are divided into three classes based on their structure and lipid substrate preferences (Vivanco and Sawyers, 2002) . Members of the class IA PI3K family are heterodimers that become activated following stimulation of various cytokine or growth factor receptors, and thus are pivotal regulators of cell proliferation and antiapoptosis. The regulatory subunit is responsible for the recruitment of the PI3K complex from the cytoplasm to the cell membrane, whereas the catalytic subunit generates the second messenger phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ) by phosphorylation of its substrate phosphatidylinositol 4,5-bisphosphate (PIP 2 ). Three isoforms of the catalytic subunit, p110a, -b and -d, are known and share structural characteristics, including helical and kinase domains, as well as binding sites for the regulatory subunit and RAS. The serine-threonine kinase AKT, the main effector of PI3K signaling, becomes activated after recruitment to PIP 3 and subsequent phosphorylation on threonine 308 in the kinase domain and serine 473 within the hydrophobic motif.
Constitutive activation of the PI3K-AKT pathway has been frequently reported in solid tumors, as also in hematological neoplasia, including T-non-Hodgkin's lymphoma (Schade et al., 2006) , mantle cell lymphoma (Rudelius et al., 2006) , diffuse large B-cell lymphoma (Uddin et al., 2006 ), Hodgkin's lymphoma (Dutton et al., 2005) , myelodysplastic syndrome and AML (Xu et al., 2003) . PI3K-AKT activation in human malignancies has been linked to both amplification/overexpression of PI3K or AKT and loss of negative regulation, due to mutation of the tumor suppressor PTEN (phosphatase and tensin homologue deleted on chromosome ten). Recently, activating point mutations in the catalytic subunit p110a of class IA PI3K have been identified, which are clustered in small hotspot regions within the helical (E542, E545) and kinase domain (H1047; Samuels et al., 2004) . These point mutations have been observed in clinical samples of solid tumors with high frequency (Bachman et al., 2004; Broderick et al., 2004; Campbell et al., 2004; Lee et al., 2005; Levine et al., 2005; Li et al., 2005) .
In AML, constitutive activation of the PI3K-AKT cascade is observed in 50-80% of all cases (Xu et al., 2003; Min et al., 2004; Grandage et al., 2005) and correlates with poor prognosis (Min et al., 2003; Kornblau et al., 2006) . PI3K activation has been reported to be necessary for the survival of AML blasts and its pharmacological inhibition is effective in vitro and in vivo (Zhao et al., 2004; Recher et al., 2005; Sujobert et al., 2005) , suggesting that targeting of this pathway with small molecule inhibitors may be a promising therapeutical option for the treatment of AML. Multiple mechanisms should be considered as an underlying cause for upregulated PI3K-AKT signaling in AML. First of all, the PI3K-AKT axis is a relevant signaling pathway for class III receptor tyrosine kinases (RTK), including FLT3 and c-KIT, which are commonly activated in AML due to internal tandem duplications or point mutations (Frohling et al., 2005) . Constitutive activation of the PI3K-AKT pathway may also result from Ras mutations that are present in up to 20% of AML (Schubbert et al., 2007) . Apart from activation of these upstream targets, other mechanisms have been described, including overexpression of the p110d isoform of PI3K (Sujobert et al., 2005) , downregulation of PTEN (Zhang et al., 2006) , mutation of the inositol 5-phosphatase 1 (Luo et al., 2003) and p110a point mutation (Lee et al., 2005) .
We and others demonstrated previously that inhibition of the PI3K-AKT pathway is sufficient to block the proliferation and survival of myeloid cells expressing c-KIT mutants, delineating the PI3K-AKT cascade to be a critical downstream mediator of deregulated c-KIT (Hashimoto et al., 2003; Shivakrupa et al., 2003; Cammenga et al., 2005) . To further analyse the relevance of an activated PI3K-AKT pathway in AML, we determined (1) whether point mutations in the catalytic (p110a) and regulatory (p85a) subunit of class IA PI3K are functional in hematopoietic cells and (2) if deregulated PI3K-AKT signaling contributes to leukemic transformation in vivo. We observed that both mutations in the helical and kinase domain of p110a led to constitutive activation of the PI3K-AKT signaling pathway, which resulted in interleukin 3 (IL3)-independent proliferation of early hematopoietic cells. Factorindependent growth was abrogated following PI3K or AKT inhibition. Balb/C mice, used in a syngenic transplantation model, were rapidly engrafted by cells carrying mutant p110a and died early due to a malignant neoplastic disease. Our model demonstrates the functional activity of p110a mutations in hematological cells in vitro and in vivo and indicates that deregulated p110a signaling can be causally involved in the transformation process of hematopoietic neoplasia.
Results
Mutant PIK3CA, but not PIK3R1, confer IL3-independent growth to hematopoietic cells To evaluate the transforming potential of an activated PI3K-AKT pathway downstream of class III receptor tyrosine kinases in hematopoietic cells, mutants of either PIK3CA, encoding the p110a catalytic subunit, or PIK3R1, encoding the p85a regulatory subunit of class IA PI3K, were tested for their ability to stimulate proliferation and inhibit apoptosis of early hematopoietic cells. P110a mutants carrying either one of the two point mutations in the helical domain (E542K, E545A) or one mutation in the kinase domain (H1047R), which have been identified in human neoplasms, were generated by site-directed mutagenesis. As positive control for an activated catalytic subunit, we created p110a mutants that are constitutively localized to the cytoplasma membrane due to the addition of myristoylation or farnesylation signals (Myr-PI3K, PI3K-CAAX). For a mutated form of the regulatory subunit, we used a truncated form of p85a (p76a) that lacks most of the C-terminal SH2-domain and has been shown to be associated with an active PI3K (Jucker et al., 2002) .
All three mutant catalytic subunits of class IA PI3K demonstrated functional activity in IL3-dependent Ba/F3 cells by conferring factor-independent growth (Table 1) . Expression of either helical domain mutants 
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Ba/F3 cells were transfected with mutated forms of human class IA PI3K subunits, p110a or p85a, and directly sorted into 96-well plates at various cell concentrations in the absence of IL3. The frequency of IL3-independent growth was determined by end-point dilution and by applying the Poisson distribution. The frequency was corrected for the plating efficiency in the presence of IL3 for each culture. In two independent experiments, no factor-independent growth was obtained in untransfected Ba/F3 or in Ba/F3 cells expressing the vector, wildtype p110a, wild-type p85a or mutant p76a.
Mutant PI3K in hematopoietic cells S Horn et al gave rise to factor-independent cells at a frequency equivalent to that conferred by forms of p110a with aberrant cellular localization. In contrast, the kinase domain mutant was the most efficient p110a mutant analysed, conferring factor-independent growth at a 10-fold higher frequency. Interestingly, the mutant regulatory subunit (p76a) was unable to confer IL3 independence to Ba/F3 cells. No spontaneous factorindependent growth was observed in parental or control-transfected Ba/F3 cells expressing YFP (vector), wild-type p110a or wild-type p85a, demonstrating that overexpression of either one of the two subunits alone is not sufficient to induce factor-independent growth.
Constitutive activation of PI3K-AKT signaling in mutant p110a expressing Ba/F3 To determine if PI3K signaling is constitutively activated in factor-independent p110a mutants, activation of the PI3K effector kinase AKT was examined by western blot analysis. As shown in Figure 1 , expression of each of the p110a mutants in Ba/F3 cells resulted in constitutive phosphorylation of AKT on both threonine 308 and serine 473 ( Figure 1 , lanes 4-8). The levels of phosphorylated AKT were comparable to freshly stimulated Ba/F3 cells (lane 2). Untransfected and vector-transfected Ba/F3 cells growing in IL3-containing medium, but lysed without additional IL3-stimulation, showed minor phosphorylation levels of AKT at serine 473, whereas phosphorylation at threonine 308 was undetectable even after longer exposures (lanes 1 and 3).
The PI3K-AKT pathway is essential for growth and survival of mutant p110a expressing Ba/F3 cells To determine if the constitutive activation of the PI3K-AKT signaling pathway was essential for the factorindependent growth of hematopoietic cells with aberrant PI3K, we tested the effect of pharmacological inhibitors of PI3K, AKT and mammalian target of rapamycin (mTOR) on the growth of mutant p110a expressing Ba/ F3 cells in proliferation assays (Figure 2 ). Inhibition of PI3K and AKT resulted in a drastic and concentrationdependent reduction in the factor-independent proliferation of all mutant p110a expressing cells. Rapamycin, which inhibits the PI3K-AKT effector mTOR, led to a partial reduction in the proliferation of mutant p110a containing cells. Cells expressing helical and kinase domain mutants of p110a were more sensitive to mTOR-inhibition than cells expressing p110a with aberrant intracellular localization (p110a-CAAX, Myrp110a). The proliferation of untransfected or vectortransfected control cells, which were maintained in the presence of IL3, was also reduced after PI3K or AKT inhibition, underlining the importance of PI3K and AKT activity for the mitogenic signaling downstream of the IL3-receptor in these cells. Importantly, however, control cells were less sensitive to low concentrations of PI3K and AKT inhibitors than cells expressing p110a mutants. Rapamycin had no effect on the proliferation of control cells in the presence of IL3, and indeed, the inhibitory effect of rapamycin on factor-independent proliferation of p110a mutants could be reversed by addition of IL3 (Supplementary Figure S1 ). These results demonstrate that mTOR does not mediate the PI3K-AKT dependent proliferation response after IL3 receptor stimulation in Ba/F3 cells. Next, we determined if inhibition of mutant p110a activity only abrogated proliferation, or also interfered with cell survival. IL3-withdrawal resulted in apoptotic cell death in IL3-dependent Ba/F3 cells, as ascertained by DNA-laddering and Annexin V-staining ( Figure 3) . Similarly, inhibition of PI3K and AKT, but not mTOR, led to a strong apoptotic response in more than 90% of Ba/F3 cells expressing mutant p110a (Figure 3b Figure S1 ). The inhibitory concentration of 50% (IC 50 ) values were determined in three independent experiments, in which transfected and untransfected Ba/F3 cells were incubated with increasing con centrations of PI3K or AKT inhibitor (Table 2) . IC 50 values for both compounds were reduced by a factor of 10 for cells expressing p110a mutants as compared to untransfected or vector transfected controls, with no substantial difference between the various p110a mutants.
Taken together, these results demonstrate that aberrant activation of PI3K and its downstream effector AKT is responsible and sufficient for factor-independent proliferation and survival of IL3-dependent hematopoietic cells. Figure S4) . A critical component of the PI3K-AKT cascade is phosphoinositide-dependent kinase 1 (PDK1), which phosphorylates AKT on threonine 308 in the activation loop and possibly also serine 473 within the hydrophobic motif. Many mechanisms have been proposed to explain how PDK1 activity is regulated after PI3K-mediated generation of PIP 3 . Besides lipid binding and intracellular localization, autophosphorylation of PDK1 on serine 241 in the activation loop of PDK1 kinase domain has been shown to be critical for PDK1 activity (Casamayor et al., 1999; Wick et al., 2003) . Interestingly, pharmacological inhibition of PI3K and AKT signaling did not alter PDK1 phosphorylation on serine 244 (homologous to serine 241 in human PDK1; Figure 4) . Furthermore, H-thymidine uptake relative to DMSO controls. Parental and vector expressing Ba/F3 cells were cultured in the presence of IL3, whereas Ba/F3 cells expressing mutant p110a were maintained without growth factor. 10 4 cells per well were treated with increasing concentrations of PI3K inhibitor LY294002, AKT inhibitor Akt IV or mTOR inhibitor rapamycin for 36 h and pulsed for 24 h with 0.5 mCi per well methyl-3H thymidine. Shown is one representative experiment of three, each performed in triplicate.
Mutant PI3K in hematopoietic cells S Horn et al the autophosphorylation status of PDK1 was not altered by IL3 stimulation (data not shown). Thus in these cells, PDK1 autophosphorylation activity did not correlate with AKT phosphorylation nor was it regulated directly by PI3K activation.
As inhibition of mTOR by rapamycin only partially suppressed the proliferation of p110a mutants and was even less effective in inducing apoptosis, additional downstream effectors of PI3K-AKT must be important for the factor-independent growth of mutant p110a expressing Ba/F3 cells. Consistent with this hypothesis, constitutive phosphorylation of GSK-3b (serine 9), FoxO4 (serine 193) and FoxO1 (serine 256) was detected in p110a mutants, all of which were clearly downregulated after PI3K and AKT inhibition. The levels of phosphorylated GSK-3b and FoxO4, but not FoxO1, were much higher in factor-independent p110a mutants as compared to factor-dependent Ba/F3 cells, indicating that GSK-3b and FoxO4 may be more important for mutant p110a signaling in these cells. Figure 4 Effect of Phosphoinositide 3-kinase (PI3K) inhibition on mutant p110a signaling. PI3K inhibition leads to downregulation of AKT phosphorylation and concomitant dephosphorylation of AKT effectors in mutant p110a expressing cells. Ba/F3 cells were treated for 6 h with PI3K inhibitor LY294002 as indicated, or with DMSO. Protein phosphorylation in total cell extracts was determined by western blot analysis with phospho-specific antibodies. Shown is a composite of two independent gels prepared in parallel in the same manner and developed with same exposure times. FoxO1 antibody acts partially as a phospho-specific antibody, which was confirmed by the manufacturer. Tubulin levels served as a loading control. Balb/C mice were transplanted with 1 Â 10 6 Ba/F3 carrying either helical (E542K, E545A) or kinase (H1047R) domain mutations of p110a. As a reference, mice were also transplanted with the same number of Ba/F3 cells expressing activated c-KIT with a mutation in the tyrosine kinase domain (D814V), which is associated with several hematopoietic malignancies, including mastocytosis and AML, and which was used as a model for deregulated class III RTK. Mice transplanted with vector expressing Ba/F3 served as a negative control.
After 5 weeks, 90% of mice receiving p110a mutant cells developed a leukemia-like disease, whereas all mice in the vector control cohort were still alive ( Figure 5 ). Histological evaluation revealed that mice receiving cells expressing mutant p110a showed massive infiltration of blasts in both hematopoietic and nonhematopietic organs ( Figure 6 ). Fluorescence activated cell sorting (FACS) analysis demonstrated a median chimerism of 44% in the bone marrow and 35% in peripheral blood in diseased mice (Figure 6b ). Tumor cell invasion of the spleen and liver resulted in hepatosplenomegaly and loss of normal organ architecture (Figure 6c and Table 3 ). Further signs of a systemic hematopoietic disease included reduced body weight and low hematocrit values, due to expulsion of erythropoiesis from the bone marrow and spleen (Table 3) . These results confirm that mutant p110a confers leukemogenic potential to hematopoietic cells.
Interestingly, all mice receiving cells expressing activated c-KIT (D814V) developed a leukemia-like disease within 9 days after transplantation, thus with significantly reduced survival rates as mutant p110a allografted mice ( Figure 5 ). Similar to mutant p110a, activated c-KIT resulted in rapid, syngenic engraftment and spread into bone marrow (52% median chimerism) and peripheral blood (54%) and induced severe anemia (Table 3 ). The reduced survival of c-KIT allografted mice as compared to mutant p110a allografted mice was confirmed by transplanting independently generated cells, which contained either the same (D814V) or a second type of activating c-KIT mutation (V558D). These results suggest that other downstream signaling pathways of c-KIT may cooperate with activated PI3K in leukemia progression.
Discussion
The PI3K-AKT pathway is frequently upregulated in human malignancies, including solid tumors and hematopoietic neoplasia, and represents an important therapeutic target (Martelli et al., 2006) . We have investigated the importance of this pathway in leukemia by expressing mutant forms of the catalytic subunit of class IA PI3K in hematopoietic cells. Our results demonstrate that helical and kinase domain mutants of p110a are functional in hematopoietic cells and constitutively activate PI3K and the PI3K-AKT pathway, comparable to PI3K activation by myristoylation or farnesylation signals. Furthermore, the activated PI3K-AKT pathway was sufficient to stimulate the survival and proliferation of hematopoietic cells, conferring factor-independent growth in vitro and leukemic transformation in vivo. The hematopoietic transforming activity of the kinase domain (H1047R) mutant appeared to be slightly stronger in vitro, but was comparable to helical domain (E542K and E545A) mutants in vivo. Similarly, no differences in the transformation potential of these two types of mutants have been found in fibroblasts or colon cancer cells (Ikenoue et al., 2005; Kang et al., 2005; Samuels et al., 2005) . Interestingly, a K227E mutation within the RASinteraction region of p110a was unable to induce either focus formation in mouse fibroblasts or cytokineindependent growth of hematopoietic cells, although elevated basal lipid kinase activity was observed (Rodriguez-Viciana et al., 1996; Shelton et al., 2004) . Thus the criteria for activating mutations within the PI3K catalytic subunit that are sufficient to induce or promote transformation in solid tumors or leukemia appear to be similar. Importantly, the transforming activity of mutant c-KIT (D814V) in vivo was significantly stronger than that of the p110a point mutations, In addition to mutations in the catalytic subunit of class IA PI3K, several mutations of the regulatory subunit p85a have been described that result in constitutive PI3K activation. In addition to p85a mutants with deletions in the inter-SH2 region, which have been identified in human colon and ovarian tumors and cancer cell lines (Philp et al., 2001) , two Cterminally truncated versions of p85a have been identified in lymphomas. In our study, we assayed the transforming ability of p76a, which has been identified in the human lymphoma cell line CO and lacks most of the negative regulatory C-terminal SH2-domain (Jucker et al., 2002) . Although association of p76a with an active p110a has been shown and PI3K activity is essential for the proliferation and survival of CO lymphoma cells, we did not observe any transforming activity of p76a in Ba/F3 cells. This is in contrast to the p65a mutant, which was isolated from a murine thymic lymphoma and which was able to transform mouse Sublethally irradiated Balb/C mice received 10 6 Ba/F3 cells stably expressing mutant p110a (E542K, n ¼ 12; E545A, n ¼ 10; H1047R, n ¼ 7), mutant c-Kit (D814V, n ¼ 5) or the vector (n ¼ 7) by tail-vein injection. Time point of analysis varied according to survival of allografted mice. Vector control mice were sacrificed 3-5 weeks after transplantation and analyzed in parallel with mutant p110a allografted mice.
fibroblasts in vitro and to induce a lymphoproliferative disorder in transgenic mice (Jimenez et al., 1998; Borlado et al., 2000) . Thus, the slightly more shortened p65a mutant seems to have higher transforming activity than p76a. Importantly, the inability of p76a to promote factor independence in Ba/F3 cells may also be attributable to interference by wild-type p85a, which is absent in CO cells, or due to other cooperating mutations in CO cells that may contribute to the transforming capacity of p76a. Earlier work has demonstrated that the activated but nontransforming K227E p110a mutant synergizes with an activated form of MEK1 in transformation of hematopoietic cells (Shelton et al., 2004) . Further work is necessary to determine the requirements for activating p85a mutations in the transformation process of hematopoietic cells.
The serine-threonine kinase AKT is a critical effector of activated PI3K. The importance of AKT in the factor-independent growth of Ba/F3 hematopoietic cells was confirmed by phosphorylation and inhibition studies. PI3K or AKT inhibition correlated with a drastic abrogation of cell proliferation and induction of apoptosis, which could be attributed to a number of different downstream targets. Although mTOR is a major downstream target of AKT and relevant transcriptional coordinator, our observations suggest that signaling of mutant p110a does not exclusively rely on mTOR in hematopoietic cells. The inhibition of mTOR activity by rapamycin suppressed the proliferation of p110a mutants but to a lesser degree to that of AKT and PI3K inhibitors. More dramatic, however, was the inability of rapamycin to block survival signals mediated by PI3K activation, indicating that mTOR is involved in the mitogenic, but not antiapoptotic signaling downstream of mutant p110a.
Other potential downstream targets of PI3K-AKT that could provide both the mitogenic and antiapoptotic effects observed are the serine-threonine protein kinase GSK-3b and Forkhead-related transcription factors, including FoxO1 and FoxO4 (formerly FKHR and AFX, respectively). Inhibition of PI3K and AKT correlated with dephosphorylation of all three proteins, but GSK-3b and FoxO4 were preferentially targeted by mutant p110a (but not IL3 signaling pathways) in our system. The phosphorylation and inactivation of GSK3b and FoxO proteins may contribute to the leukemic phenotype by interfering with the c-Myc pathway. GSK-3b controls proteolysis of c-Myc (Gregory et al., 2003) , which is upregulated in many hematopoietic malignancies, by a variety of mechanisms, and aberrantly stabilized in ALL (Hoffman et al., 2002; Malempati et al., 2006) . In contrast, FoxO proteins co-regulate many of the c-Myc target genes involved in proliferation, such as D-cyclins and cell cycle inhibitors, including p21Cip1 and p27Kip1 (Bouchard et al., 2004; Martelli et al., 2006) . Interestingly, the differential phosphorylation status of GSK-3b and FoxO4 in response to wild-type and mutant p110a clones was not previously observed in solid tumors (Samuels et al., 2005) , but is consistent with increased levels of AKTdependent GSK-3b phosphorylation in chicken embryonic fibroblasts expressing p110a-H1047R (Bader et al., 2006) . These results support the conclusion that the cell context may be extremely important in determining the downstream effectors of activated PI3K-AKT and associated signaling components, and thus have important implications for therapeutic targeting. The specific and significant targeting of GSK-3b and FoxO4 by activated PI3K in our system suggests that further examination of these downstream targets in AML samples is warranted.
In summary, our results demonstrate that constitutive activation of the PI3K catalytic subunit promotes proliferation, survival and oncogenic growth of hematopoietic cells, supporting its putative role in the transformation process of hematological neoplasms in concert with other hits that disturb cellular differentiation, as has been proposed in the multistep model of leukemogenesis (Gilliland and Griffin, 2002) . In the majority of AML with an activated PI3K-AKT pathway, this is attributable to activation of upstream kinases, such as RTK or RAS mutations. Significantly, we have shown that p110a mutants carrying point mutations in the helical and kinase domain, which are found frequently in solid tumors, are sufficient to activate the PI3K-AKT pathway in hematopoietic cells. In accord with our data, the helical mutant E545A of p110a has also been observed in acute leukemia (Lee et al., 2005) . However, it is important to note that mutations in PIK3CA (encoding p110a) appear to be rare events in AML (Bousquet et al., 2005; Hummerdal et al., 2006; Muller et al., 2007) . In light of our data and the recent demonstration that the p110d isoform is a critical PI3K subunit in AML (Sujobert et al., 2005; Billottet et al., 2006) , it may be important to screen other class IA PI3K genes. Alternatively, mutations in the PI3K catalytic subunit may be rare in AML because hematopoietic cells seem to have only a limited selection advantage without the simultaneous activation of multiple signaling pathways, as stimulated by RTK mutants such as c-KIT. This hypothesis is supported by our syngenic mouse model showing more rapid disease by mutant c-KIT in comparison to mutant p110a. Our data suggest that further investigation of the PI3K-AKT pathway and cooperating signaling cascades to elucidate their role in leukemogenesis and to identify potential inhibitory treatment strategies is warranted.
Materials and methods

Generation of mutant p110a
Full-length cDNA of the human PIK3CA gene, which encodes p110a, was generated from RNA prepared from TF-1 cells and tagged with an influenza hemagglutinin (HA) epitope at the amino-terminal end by PCR amplification. P110a with point mutations in the helical (E542K, E545A) or kinase (H1047R) domains were created by site-directed mutagenesis using the QuickChange mutagenesis kit (Stratagene, La Jolla, CA, USA). As positive controls for growth stimulation, constitutively activated p110a mutants, containing membrane localization signals from chicken src (Myr-p110a) or human h-ras (p110a-CAAX), were generated as described (Klippel et al., 1996) . Wild-type and mutant p110a were inserted into the pSF91-I-YFP-PRE retroviral vector, which carries the yellow fluorescence protein (YFP) as marker. The same vector was used for expressions of the wild-type (p85a) and mutated forms (p76a) of the regulatory subunit of class IA PI3K (PIK3R1), described previously (Jucker et al., 2002) . Wild-type and mutant PI3Ka constructs were verified by sequence analysis.
Cell culture
Ba/F3 cells were cultured in RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum (Sigma, Taufkirchen, Germany), 2 mM glutamine, 1 mM sodium pyruvate and 5% (v/v) conditioned medium containing mouse IL3. Cells were treated with the PI3-kinase inhibitor LY294002, the AKT inhibitor Akt IV or the mTOR inhibitor rapamycin (Calbiochem/EMD Biosciences, San Diego, CA, USA) for various times and concentrations, as indicated in the figure legends. Control cells were treated with the same amount of dimethyl sulfoxide (DMSO) used as inhibitor solvent. For stimulation, cells were maintained for 16 h in the absence of IL3 at a density of 5 Â 10 5 cells ml
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. Cells were resuspended in the same medium at a density of 10 7 cells ml À1 and stimulated with 100 ng ml À1 recombinant mouse IL3 for 5 min. Cell proliferation was evaluated by methyl-3H thymidine uptake as described (Cammenga et al., 2005) . Survival assays were performed using the apoptosis detection kit (BD Pharmingen, San Diego, CA, USA). Early and late apoptosis were determined by flow cytometry on a FACS Canto (BD Biosciences, San Jose, CA, USA) according to the manufacturer's instructions.
Generation of mutant PI3Ka expressing cells
Cells were transfected with 10 mg plasmid containing wild-type or mutant cDNA of either the catalytic (p110a) or the regulatory (p85a) subunit by electroporation at 300 V and 1050 mF (Easyjec T electroporation system; Eurogentec, Seraing, Belgium). Transfected cells were selected for IL3-independent growth in medium without IL3. To calculate the frequency of IL3-independent growth, transfected cells were identified by FACS and directly sorted into 96-well plates with or without IL3. IL3-independent growth was determined by end-point dilution and applying the Poisson distribution, as described previously (Stocking et al., 1993) .
Protein analysis
To avoid rapid degradation of cellular proteins due to high protease activity, Ba/F3 cells were lysed directly in cold 150 mM NaCl supplemented with 10% (w/v) trichloroacetic acid (TCA). Cell extracts were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and immunoblotted on polyvinylidene difluoride (PVDF) membranes. Protein phosphorylation and expression levels were detected with antibodies against phospho-T308-AKT, phospho-S473-AKT, phospho-S256-FoxO1, phospho-S193-FoxO4, phospho-S9-GSK-3b, phospho-S241-PDK1, FoxO1, FoxO4, GSK-3b, PDK1, p110a (Cell Signaling Technology, Beverly, MA, USA), AKT1 (C-20, sc-1618, Santa Cruz Biotechnology, Santa Cruz, CA, USA), HA (clone 3F10, Roche Diagnostics, Mannheim, Germany) and a-tubulin (CP06, Merck Chemicals Ltd, Nottingham, UK). Chemiluminescence detection was performed using the appropriate secondary antibody conjugated with horseradish peroxidase and the ECL system according to the manufacturer's description (Amersham Biosciences, Buckinghamshire, UK). PVDF membranes were reprobed after removal of the antibodies from the filter by incubation in 62.5 mM Tris pH 6.8, 2% (v/v) SDS and 100 mM b-mercaptoethanol for 15 min at 70 1C.
Animal studies
Sublethally irradiated (4.5 Gy) 8-12 week-old Balb/C mice received 10 6 Ba/F3 cells expressing mutant p110a or c-KIT by tail vein injection. Morphologic and histologic analysis of moribund mice or killed control mice was performed using standard protocols. Hematopoietic tissues were analysed for YFP positive cells by FACS analysis of single-cell suspensions. Peripheral blood smears and cytospins of bone marrow cells harvested from tibiae and femora were stained with MayGru¨nwald and Giemsa stains (Sigma) according to the Pappenheim method. Tissue samples of liver and spleen were fixed in 4% (v/v) formalin and embedded in paraffin. Deparaffinated sections were stained with H&E (Sigma), as described previously (Schwieger et al., 2002) .
